Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR132L in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
NCT05953831Phase 2Withdrawn
- Sponsor
- Cardior Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
A Phase 2 trial of CDR132L in heart failure with preserved ejection fraction (HFpEF), sponsored by Cardior Pharmaceuticals. Planned start Apr 2024; status: withdrawn.
02
Drugs
CDR132L
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05953831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953831.